公开(公告)号：US20230293540A1

公开(公告)日：2023-09-21

申请号：US18179160

申请日：2023-03-06

Applicant: Elixir Medical Corporation

Inventor： John Yan ,  Xiaoxia Zheng ,  Vinayak D. Bhat ,  Motasim Sirhan ,  Margaret Wong ,  Blaine Bueche

IPC: A61K31/5377 ,  A61K9/00 ,  A61K31/4545 ,  A61K47/10 ,  A61P27/02

CPC classification number: A61K31/5377 ,  A61K9/0019 ,  A61K9/0048 ,  A61K31/4545 ,  A61K47/10 ,  A61P27/02

Abstract: Devices, formulations, compositions, and methods are provided for inhibiting an inflammatory ophthalmic disease or eye condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor II inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory ophthalmic disease or condition in the patient’s eye(s). The therapeutic composition may be formulated for delivery to the patient by via injection, an implant, an eye drop, an emulsion, a suspension, an ointment, a nanomicelle, a nanoparticle, a nanosuspension, a liposome, an in-situ gel, a contact lens, or a microneedle or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents. The one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents may be delivered together with the direct factor Xa inhibitor and/or direct factor IIa inhibitor, or separately from the direct factor Xa inhibitor and/or direct factor IIa inhibitor.